Jean Baptiste Beauval

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3128983/publications.pdf

Version: 2024-02-01

361413 243625 2,102 51 20 44 g-index citations h-index papers 63 63 63 2760 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	How PET-CT is Changing the Management of Non-metastatic Castration-resistant Prostate Cancer?. Progres En Urologie, 2022, 32, 32/6S43-32/6S53.	0.8	1
2	Narrative review of PET/CT performances at biochemical recurrence in prostate cancer after radical prostatectomy and impact on patient disease management. Progres En Urologie, 2022, 32, 32/6S33-32/6S42.	0.8	0
3	Endoscopic enucleation for prostate larger than 60ÂmL: comparison between holmium laser enucleation and plasmakinetic enucleation. World Journal of Urology, 2021, 39, 2011-2018.	2.2	9
4	Robotic-assisted kidney transplantation in obese recipients compared to non-obese recipients: the European experience. World Journal of Urology, 2021, 39, 1287-1298.	2.2	30
5	The prognostic value of high-grade prostate cancer pattern on MRI-targeted biopsies: predictors for downgrading and importance of concomitant systematic biopsies. World Journal of Urology, 2021, 39, 3315-3321.	2.2	6
6	Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers, 2021, 13, 4251.	3.7	17
7	Performance of systematic, MRI-targeted biopsies alone or in combination for the prediction of unfavourable disease in MRI-positive low-risk prostate cancer patients eligible for active surveillance. World Journal of Urology, 2020, 38, 663-671.	2.2	10
8	Active surveillance eligibility of MRI-positive patients with grade group 2 prostate cancer: a pathological study. World Journal of Urology, 2020, 38, 1735-1740.	2.2	6
9	The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. European Urology, 2020, 77, 733-741.	1.9	85
10	Decreased accuracy of the prostate cancer EAU risk group classification in the era of imaging-guided diagnostic pathway: proposal for a new classification based on MRI-targeted biopsies and early oncologic outcomes after surgery. World Journal of Urology, 2020, 38, 2493-2500.	2.2	20
11	Impact of MRI and Targeted Biopsies on Eligibility and Disease Reclassification in MRI-positive Candidates for Active Surveillance on Systematic Biopsies. Urology, 2020, 137, 126-132.	1.0	7
12	One-day Prehabilitation Program Before Robotic Radical Prostatectomy in Daily Practice: Routine Feasibility and Benefits for Patients and Hospitals. European Urology Open Science, 2020, 21, 14-16.	0.4	6
13	Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging–targeted Biopsy. European Urology Oncology, 2020, 3, 739-747	5.4	31
14	Confirmation by Early Oncologic Outcomes After Surgery of the Accuracy of Intermediate-risk Prostate Cancer Classification Based on Magnetic Resonance Imaging Staging and Targeted Biopsy. European Urology Open Science, 2020, 21, 5-8.	0.4	3
15	A combination of enhanced recovery after surgery and prehabilitation pathways improves perioperative outcomes and costs for robotic radical prostatectomy. Cancer, 2020, 126, 4148-4155.	4.1	41
16	Improvement of the intermediate risk prostate cancer sub-classification by integrating MRI and fusion biopsy features. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 386-392.	1.6	4
17	Deep Neural Networks Outperform the CAPRA Score in Predicting Biochemical Recurrence After Prostatectomy. Frontiers in Oncology, 2020, 10, 607923.	2.8	7
18	Predicting biochemical recurrence after prostatectomy: Can machine learning beat CAPRA score? Results of a multicentric retrospective analysis on 4,700 patients Journal of Clinical Oncology, 2020, 38, 343-343.	1.6	1

#	Article	IF	CITATIONS
19	Laparoscopy for living donor left nephrectomy: Comparison of threeâ€dimensional and twoâ€dimensional vision. Clinical Transplantation, 2019, 33, e13745.	1.6	4
20	A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study). Urologic Oncology: Seminars and Original Investigations, 2019, 37, 577.e1-577.e7.	1.6	4
21	Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study. World Journal of Urology, 2019, 37, 1491-1498.	2.2	7
22	Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study). Progres En Urologie, 2019, 29, 282-287.	0.8	3
23	Evaluation of the impact of a clinical pathway on the progression of acute urinary retention. Neurourology and Urodynamics, 2019, 38, 387-392.	1.5	6
24	Migration in last decade to high-risk prostate cancer after radical prostatectomy. Progres En Urologie, 2019, 29, 29-35.	0.8	3
25	A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. European Urology, 2019, 75, 506-514.	1.9	188
26	Impact of hospital volume and surgeon volume on robotâ€assisted partial nephrectomy outcomes: a multicentre study. BJU International, 2018, 121, 916-922.	2.5	47
27	Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR. Progres En Urologie, 2018, 28, 146-155.	0.8	13
28	Long-term oncological outcomes after robotic partial nephrectomy for renal cell carcinoma: a prospective multicentre study. World Journal of Urology, 2018, 36, 897-904.	2.2	23
29	Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. Critical Reviews in Oncology/Hematology, 2018, 122, 144-149.	4.4	13
30	Management of non-metastatic castrate-resistant prostate cancer: A systematic review. Cancer Treatment Reviews, 2018, 70, 223-231.	7.7	17
31	Total intracorporeal robotic renal auto-transplantation: A new minimally invasive approach to preserve the kidney after major ureteral injuries. International Journal of Surgery Case Reports, 2018, 49, 176-179.	0.6	12
32	Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 2018, 379, 417-427.	27.0	684
33	CARMENA: Cytoreductive nephrectomy followed by sunitinib versus sunitinib alone in metastatic renal cell carcinomaâ€"Results of a phase III noninferiority trial Journal of Clinical Oncology, 2018, 36, LBA3-LBA3.	1.6	10
34	Predictive model of 1-year postoperative renal function after living donor nephrectomy. International Urology and Nephrology, 2017, 49, 793-801.	1.4	11
35	External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. Prostate, 2017, 77, 928-933.	2.3	8
36	Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study. Urologia Internationalis, 2017, 99, 272-276.	1.3	16

#	Article	IF	CITATIONS
37	Improved decision making in intermediate-risk prostate cancer: a multicenter study on pathologic and oncologic outcomes after radical prostatectomy. World Journal of Urology, 2017, 35, 1191-1197.	2,2	10
38	Ductal adenocarcinoma of the prostate: Clinical and biological profiles. Prostate, 2017, 77, 1242-1250.	2.3	26
39	Current impact of age and comorbidity assessment on prostate cancer treatment choice and over/undertreatment risk. World Journal of Urology, 2017, 35, 587-593.	2.2	29
40	Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors. Annals of Surgical Oncology, 2016, 23, 4277-4283.	1.5	121
41	Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer. BMC Urology, 2016, 16, 26.	1.4	23
42	Laparoscopic nephrectomy for polycystic kidney: comparison of the transperitoneal and retroperitoneal approaches. World Journal of Urology, 2016, 34, 901-906.	2.2	16
43	The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery. World Journal of Urology, 2016, 34, 347-352.	2.2	40
44	Patient selection for laparoscopic excision of adrenal metastases: A multicenter cohort study. International Journal of Surgery, 2015, 24, 75-80.	2.7	15
45	The use of hemostatic agents does not prevent hemorrhagic complications of robotic partial nephrectomy. World Journal of Urology, 2015, 33, 1815-1820.	2.2	16
46	What risk of prostate cancer led urologist to recommend prostate biopsies?. Progres En Urologie, 2015, 25, 1125-1131.	0.8	2
47	External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer. BJU International, 2014, 114, E113-E119.	2.5	10
48	Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?. World Journal of Urology, 2014, 32, 109-114.	2.2	87
49	Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study. World Journal of Urology, 2014, 32, 1331-1338.	2.2	23
50	Pathologic Findings in Radical Prostatectomy Specimens From Patients Eligible for Active Surveillance With Highly Selective Criteria: A Multicenter Study. Urology, 2012, 80, 656-660.	1.0	60
51	Radical Prostatectomy for High-risk Prostate Cancer Defined by Preoperative Criteria: Oncologic Follow-up in National Multicenter Study in 813 Patients and Assessment of Easy-to-use Prognostic Substratification. Urology, 2011, 78, 607-613.	1.0	55